{"id":"NCT03696108","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)","officialTitle":"A Phase 3, Randomized, Double-blind Clinical Study to Evaluate the Long-term Safety and Efficacy of MK-7264 in Japanese Adult Participants With Refractory or Unexplained Chronic Cough","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-31","primaryCompletion":"2020-10-07","completion":"2020-10-07","firstPosted":"2018-10-04","resultsPosted":"2021-11-01","lastUpdate":"2021-11-01"},"enrollment":175,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Cough"],"interventions":[{"type":"DRUG","name":"Gefapixant","otherNames":["MK-7264"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Gefapixant 15 mg BID","type":"EXPERIMENTAL"},{"label":"Gefapixant 45 mg BID","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.","primaryOutcome":{"measure":"Number of Participants Who Experienced at Least One Adverse Event (AE)","timeFrame":"Up to 54 Weeks","effectByArm":[{"arm":"Gefapixant 15 mg BID","deltaMin":79,"sd":null},{"arm":"Gefapixant 45 mg","deltaMin":82,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":61,"countries":["Japan"]},"refs":{"pmids":["35752582"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":84},"commonTop":["Nasopharyngitis","Dysgeusia","Cough","Hypogeusia","Taste disorder"]}}